Bispecific Toxicity Management in DLBCL Care

EP: 1.Bispecific Antibodies in DLBCL: Therapeutic Potential

EP: 2.Efficacy Insights on Bispecific Antibodies in DLBCL

EP: 3.Bispecific Antibodies in DLBCL Trials

EP: 4.Bispecific Antibodies in DLBCL: Patient Response

EP: 5.Future Insights on Bispecific Therapies

EP: 6.Overcoming DLBCL Treatment Hurdles

EP: 7.Patient Education and Monitoring in DLBCL Treatment

EP: 8.Implementing Bispecific Treatments

Now Viewing

EP: 9.Bispecific Toxicity Management in DLBCL Care

EP: 10.Multidisciplinary Bispecific Care

EP: 11.Pharmacists: Bispecifics and Operational Role

EP: 12.Strategies for Reducing Bispecific Therapy Toxicities

EP: 13.Unmet Needs in Bispecific Therapy Access

EP: 14.Implementing Bispecific Antibodies in Lymphoma Care

This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.

In this segment, Mahmoudjafari interviews Mancini, discussing significant advancements and risk management associated with bispecific therapies in DLBCL. Mancini breaks down the 2 distinct phases of toxicity management: early phase, focusing on cytokine release syndrome (CRS), neurotoxicity, and tumor flares; and maintenance phase, addressing infection risks.

Mancini emphasizes the importance of following chimeric antigen receptor T-cell therapy guidelines for CRS and neurotoxicity management during the early phase, with corticosteroids as a go-to recommendation. He challenges the necessity of tocilizumab up front, asserting its potential additional costs and logistical challenges. In the maintenance phase, infection risks become a primary concern, highlighting T cell exhaustion and hypogammaglobulinemia. Prophylaxis measures, including antiviral and pneumocystis pneumonia prophylaxis, are crucial. Mancini addresses the hesitancy of some centers in providing maintenance due to past adverse effects but stresses the importance of infection prevention as a standard in oncology. The discussion underscores the need for comprehensive monitoring and proactive measures for long-term adverse effects in bispecific therapy.

This summary was AI-generated and reviewed by Pharmacy Times^® editorial staff.